Promoting Altruism to Enhance Vaccine Acceptance
Study Details
Study Description
Brief Summary
Subjects enrolled in this study are eligible for the seasonal influenza vaccine. The purpose of this research study is to figure out if increasing individuals' awareness of the benefits of herd immunity, specifically to the local pediatric oncology community, can improve vaccination uptake rates.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The purpose of this study is to identify associations with influenza vaccine hesitancy, including parental demographics and altruism score, in families with healthy children attending two pediatric practices.
Also, in the cohort of families with baseline vaccine hesitancy, to assess the effectiveness of a pilot educational intervention focusing on the development of herd immunity for pediatric oncology patients by measuring:
-
The change in vaccine hesitancy scores pre- and post-intervention.
-
The rate of influenza vaccine uptake compared to historic controls from previous influenza seasons.
Another aim is to explore the relationship between baseline influenza vaccine hesitancy rates and baseline altruism scores. Effectiveness of this intervention is dependent on parental altruism levels; therefore, the study team also seeks to determine if there is an association between parental altruism and vaccine hesitancy for their children.
This is a single-arm prospective cohort study. The study will enroll legal guardians of children who are influenza vaccine-eligible to measure their vaccine hesitancy scores, altruism scores, and the impact of an educational intervention focused on herd immunity on the guardians' vaccine hesitancy score.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Vaccine Hesitant Subjects who consent to this study and deemed vaccine hesitant, they will receive an educational intervention. |
Behavioral: educational intervention
If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average > 3), they will be given the informational handout along with a brief script.
|
Outcome Measures
Primary Outcome Measures
- Change in Vaccine Hesitancy Scores Pre- and Post-Intervention. [baseline]
8-item Vaccine Hesitancy Scale. Subjects identified as vaccine-hesitant based on a Vaccine Hesitancy Score >/= 3. Score range is 1-5 and > or = 3 is considered vaccine hesitant.
- Pre-Intervention Vaccine Hesitancy Score [baseline]
8-item Vaccine Hesitancy Scale. Subjects identified as vaccine-hesitant based on a Vaccine Hesitancy Score >/= 3. Score range is 1-5 and > or = 3 is considered vaccine hesitant.
- Post-Intervention Vaccine Hesitancy Score [baseline]
8-item Vaccine Hesitancy Scale. Subjects identified as vaccine-hesitant based on a Vaccine Hesitancy Score >/= 3. Score range is 1-5 and > or = 3 is considered vaccine hesitant.
Secondary Outcome Measures
- Rate of Influenza Vaccine Uptake [baseline]
The subject's child's electronic health record will be accessed to document whether that patient received the seasonal influenza vaccine during the baseline visit.
- Pre-Intervention Altruism Scale [baseline]
Scale ranges from 20-100 with a higher score denoting higher altruism.
Other Outcome Measures
- Complex Interaction Interviews [Month 9]
Motivational interviews will be conducted with 20 vaccine-hesitant participants, and with four study volunteers. Each motivational interview will be conducted by the same person. Data from these interviews will be entered directly into a Research Electronic Data Capture database and analyzed using Statistical Analysis Software (SAS v9.4).
Eligibility Criteria
Criteria
Inclusion Criteria:
- All legal guardians of children aged 6 months and up who are influenza vaccine-eligible and present to the pediatric clinic.
Exclusion Criteria:
- Legal guardians of children who are not influenza vaccine-eligible including children less than 6 months of age, children on immunosuppressive medications, and children with underlying medical conditions resulting in an immunocompromised state.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Wake Forest Univesity Health Sciences | Winston-Salem | North Carolina | United States | 27157 |
Sponsors and Collaborators
- Wake Forest University Health Sciences
Investigators
- Principal Investigator: Elizabeth Halvorson, MD, Wake Forest University Health Sciences
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB00068446